Τ-형 칼슘 채널에 활성을 지닌 신규 1,4-다이아제판 피라졸 화합물
    61.
    发明公开
    Τ-형 칼슘 채널에 활성을 지닌 신규 1,4-다이아제판 피라졸 화합물 有权
    作为T型钙通道拮抗剂的1,4-二氮杂双环衍生物

    公开(公告)号:KR1020120097288A

    公开(公告)日:2012-09-03

    申请号:KR1020110016788

    申请日:2011-02-24

    Abstract: PURPOSE: A pharmaceutical composition containing 1,4-diazepane pyrazole compound and a pharmaceutically acceptable salt thereof is provided to be used as an agent for preventing or treating brain diseases, heart diseases, cancer, epilepsy, and pain. CONSTITUTION: A 1,4-diazepane pyrazole compound is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating brain diseases such as epilepsy, depression, Parkinson's diseases, dementia, sleep disorders, or heart diseases such as hypertension, cardiac arrhythmia, or myocardial infarction, or pain contains the compound of chemical formula 1 as an active ingredient. A method for preparing the compound of chemical formula 1 comprises a step of reacting pyrazolemethyl amine of chemical formula 2 with chloroacetyl chloride.

    Abstract translation: 目的:提供含有1,4-二氮杂环庚烷吡唑化合物及其药学上可接受的盐的药物组合物,用作预防或治疗脑疾病,心脏病,癌症,癫痫和疼痛的药剂。 构成:1,4-二氮杂环庚烷吡唑化合物由化学式1表示。用于预防和治疗脑疾病如癫痫,抑郁症,帕金森病,痴呆,睡眠障碍或心脏病如高血压,心律失常, 或心肌梗塞,或疼痛含有化学式1的化合物作为活性成分。 制备化学式1的化合物的方法包括使化学式2的吡唑甲胺与氯乙酰氯反应的步骤。

    T-형 칼슘 채널에 활성을 지닌 피라조일 피페리딘 화합물
    62.
    发明公开
    T-형 칼슘 채널에 활성을 지닌 피라조일 피페리딘 화합물 有权
    吡唑啉酮化合物作为T型钙通道拮抗剂

    公开(公告)号:KR1020120097287A

    公开(公告)日:2012-09-03

    申请号:KR1020110016787

    申请日:2011-02-24

    Abstract: PURPOSE: A pharmaceutical composition containing pyrazoyl piperidine compounds and pharmaceutically acceptable salt thereof is provided to prevent or treat brain diseases, heard diseases, cancer, and pain. CONSTITUTION: A pyrazoyl piperidine compound is denoted by chemical formula 1. A pharmaceutical composition for treating cerebral diseases, cardiac diseases, cancer, or pain contains the compound of chemical formula 1 as an active ingredient. A method for preparing the compound comprises: a step of reacting piperidine acetate of chemical formula 2 and pyrazole methyl amine of chemical formula 3 of a step of reacting piperidine compound of chemical formula 4 with an aldehyde compound of chemical formula 5 by reduction-amination. [Reference numerals] (AA) Reductive amination

    Abstract translation: 目的:提供含有吡唑基哌啶化合物及其药学上可接受的盐的药物组合物,以预防或治疗脑疾病,听到疾病,癌症和疼痛。 构成:化学式1表示吡唑基哌啶化合物。用于治疗脑疾病,心脏病,癌症或疼痛的药物组合物含有化学式1的化合物作为活性成分。 制备该化合物的方法包括:使化学式2的哌啶乙酸酯与化学式3的吡唑甲胺与化学式4的哌啶化合物与化学式5的醛化合物的还原胺化反应的步骤。 (参考号)(AA)还原胺化

    세로토닌 6 수용체 리간드의 고효율 검색을 위한 HA-5-HT6R을 안정적으로 발현하는 세포주
    64.
    发明授权
    세로토닌 6 수용체 리간드의 고효율 검색을 위한 HA-5-HT6R을 안정적으로 발현하는 세포주 有权
    稳定表达HA-5-HT6R的细胞系用于血清素6受体配体的高通量检测

    公开(公告)号:KR101052621B1

    公开(公告)日:2011-07-29

    申请号:KR1020080095258

    申请日:2008-09-29

    Abstract: 본 발명은 세로토닌 6 수용체 리간드의 고효율 검색방법에 관한 것으로, HA-5-HT
    6 R을 안정적으로 발현하는 세포주를 이용한 세로토닌 6 수용체 리간드의 고효율 검색방법에 관한 것이다. 본 발명의 세포주는 HA-5-HT
    6 R을 안정적으로 발현함으로써, 5-HT
    6 R에 선택적으로 작용하는 리간드의 검색 효율을 증가시키며, 5-HT
    6 R과 결합하는 단백질 연구에 유용하게 이용될 수 있다. 이에, 5-HT
    6 R이 관련된 우울증과 알츠하이머 등의 뇌질환 및 정신질환 예방과 진단 및 치료제 개발에 유용할 것이다.
    세로토닌 6 수용체, HA, 리간드, 우울증, 알츠하이머

    Abstract translation: 本发明涉及高通量检测血清素6受体配体的方法,其中HA-5-HT

    세로토닌 6 수용체 발현 세포주 및 이를 이용한 선택적 리간드의 고효율 스크리닝 방법
    66.
    发明公开
    세로토닌 6 수용체 발현 세포주 및 이를 이용한 선택적 리간드의 고효율 스크리닝 방법 无效
    通过使用IT表示选择性配置的5-HT6R和高通量筛选方法

    公开(公告)号:KR1020100096501A

    公开(公告)日:2010-09-02

    申请号:KR1020090015404

    申请日:2009-02-24

    Abstract: PURPOSE: A transformed cell line which expresses human serotonin 6 receptor(5-HT6R) is provided to stably express Myc-5-HT6R on the cell surface and to use in screening human serotonin 6-receptor-specific ligand by fluorescence imaging. CONSTITUTION: A HELA cell line stably expresses Myc-5-HT6R by transducing vector containing Myc-labeled 5-HT6R. The Myc-labeld 5-HT6R gene is a gene of sequence number 1. A HELA cell line is Hela cell(deposit number KCLRF=BR-00200) which stably expresses Myc-5-HT6R. A method for screening 5-HT6R ligand of high efficiency comprises: a step of treating test chemical to a cell line; a step of measuring 5-HT6R activity of the cell line; and a step of selecting test chemical which increases or decreases 5-HT6R in the cell line.

    Abstract translation: 目的:提供表达人血清素6受体(5-HT6R)的转化细胞系,以稳定表达细胞表面的Myc-5-HT6R,并用于通过荧光成像筛选人5-羟色胺6受体特异性配体。 构成:HELA细胞系通过转导含有Myc标记的5-HT6R的载体稳定表达Myc-5-HT6R。 Myc-labeld 5-HT6R基因是序列号1的基因.HELA细胞系是稳定表达Myc-5-HT6R的Hela细胞(保藏号KCLRF = BR-00200)。 用于筛选高效率的5-HT6R配体的方法包括:将化学试剂处理至细胞系的步骤; 测量细胞系的5-HT6R活性的步骤; 以及选择在细胞系中增加或减少5-HT6R的测试化学品的步骤。

Patent Agency Ranking